Women treated for oestrogen receptor (ER) positive breast cancer have a persistent risk of recurrence for at least 15 years after being disease free with the current standard of five years’ endocrine therapy, a large meta-analysis of long term follow-up studies has reported.1 “This finding has implications for long term follow-up strategies and highlights the need for new approaches to reduce late recurrence,” the researchers, led by Hongchao Pan, from the University of Oxford, UK, said. They added, “The risk could be reduced by extending the duration of …

中文翻译：

---

研究发现，内分泌治疗结束后，乳腺癌复发的风险仍然存在多年

根据目前的五年内分泌治疗标准，接受过雌激素受体（ER）阳性乳腺癌治疗的妇女在无疾病后至少有15年持续复发的风险，长期随访研究的一项大型荟萃分析显示，报道。1“这项发现对长期的随访策略有影响，并强调了减少晚期复发的新方法的必要性，”来自英国牛津大学的潘宏超领导的研究人员说。他们补充说：“可以通过延长……的持续时间来降低风险。